The American Medication Agency (FDA) has authorized the combined use of Dapagliflozina (10 milligrams) and Saxagliptin (5 milligrams), marketed by Astrazeneca as 'Qtern', as a daily treatment to improve glycemia controlof patients with type 2 diabetes.
The drug, which occurs in the form of tablets, is indicated as a complement to diet and physical exercise to improve blood sugar levels in adult patients in which it has not been able to control with dapagliflozine (10 milligrams) or that alreadyThey are being treated with dapagliflozine and saxagliptin.
The treatment combines two hypoglycemic agents with a complementary mechanism of action.Diadapagliflozine is an inhibitor of sodium-glucose 2 (SGLT-2) and saxagliptin an inhibitor of the peptidea-4 dipeptidyl inhibitor (DPP-4).
The approval of the FDA is based on the data of a phase III trial that confirmed its effectiveness and safety.The European Commission has already approved this combination for the treatment of type 2 diabetes in the 28 EU Most Iceland, Liechtenstein and Norway, becoming the first combination of DPP-4I/SGLT-2i authorized inEurope.
In fact, according to the company in a statement, currently this medicine is in the phase of obtaining price and reimbursement by the Spanish health authorities.
"It represents excellent news for patients with type 2 diabetes being able to benefit from better glycemia control," said the vice president and director of cardiovascular and metabolic diseases of the Department of Global Development of Medicines of Astrazeneca, Elisabeth Björk.